Halazepam and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Halazepam
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines slow down your brain and body. Buprenorphine is an opioid used for pain or for treating opioid use disorder, and halazepam is a benzodiazepine used for anxiety. When taken together, their calming effects add up. That can cause heavy drowsiness, very slow or shallow breathing, and in serious cases, unresponsiveness or worse.
This is a real and serious combination, but it is not automatically off-limits. Sometimes both are needed for a time. The important thing is that your care team knows you take both so they can watch you closely and use the lowest doses that work. Please don't stop either one on your own. Reach out to your pharmacist or doctor to talk it through.
Effect: Additive CNS and respiratory depression from concurrent buprenorphine (partial mu-opioid agonist) and halazepam (benzodiazepine). Risk includes profound sedation, respiratory depression, coma, and death.
Mechanism: Pharmacodynamic (additive CNS depression), not a metabolic/prodrug interaction. Direction: increased combined depressant effect. Evidence: probable; supported by epidemiologic overdose-death data. Onset: unspecified.
- Avoid concurrent use where possible; taper the benzodiazepine or use the lowest effective dose.
- Consider non-benzodiazepine options for anxiety/insomnia.
- If combined, monitor mental status and respiratory function; consider higher level of care.
- Do not withhold MAT solely because of CNS depressant use; the risk of untreated OUD may be greater.
What happens
An increased risk of CNS depression and respiratory depression
Interaction Deep Dive
When buprenorphine is given together with a benzodiazepine, the combined CNS depressant effects can add up and heighten the likelihood of respiratory depression, deep sedation, coma, and death. Rather than using these agents together, discontinuing the benzodiazepine or other CNS depressant is the preferred approach. Monitoring within a higher level of care or performing a taper may be suitable in certain situations. In others, it may be appropriate to slowly wean a patient off a prescribed benzodiazepine or other CNS depressant, or to reduce it to the lowest dose that remains effective. Should combined use be unavoidable, watch for respiratory depression and proceed with caution1. Swedish epidemiological research found that patients undergoing methadone- or buprenorphine-based medication-assisted treatment (MAT) who also took benzodiazepines or other CNS depressants (for instance, agents used for insomnia) faced a greater risk of death. An analysis of pooled nationwide death certificate records spanning 2010 to 2014 indicated that most overdose deaths involving buprenorphine and methadone also involved concurrent CNS depressant use. Whether buprenorphine and methadone differed in their risk of overdose death when combined with CNS depressant drugs is not known 3.
Why it happens (mechanism)
Additive CNS depression
How to manage this interaction
What your care team may do:
- Prefer avoiding the combination, often by tapering the benzodiazepine or reducing to the lowest effective dose.
- Consider non-benzodiazepine alternatives for anxiety or insomnia.
- If both are truly needed, monitor you more closely for sedation and breathing changes, sometimes in a higher level of care.
What you should do: Keep taking both exactly as prescribed unless told otherwise, and never stop them abruptly on your own. Tell your pharmacist or prescriber that you take both. Get emergency help for extreme drowsiness, confusion, or slow/shallow breathing. If buprenorphine is for opioid use disorder, do not stop it out of fear of this interaction.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
2 reports — tap to read
a) A Swedish epidemiological study reported that patients receiving methadone- or buprenorphine-based medication-assisted treatment (MAT) together with benzodiazepines or other CNS depressants (for example, drugs that treat insomnia) have an increased risk of death. Between July 1, 2005 and December 31, 2012, the risk of fatal overdose, non-overdose related mortality, and all-cause mortality was compared between periods of prescribed CNS depressants and periods without CNS depressant therapy in MAT prescribed patients (aged 18 to 50). The findings showed a higher risk of all-cause mortality (adjusted hazard ratio (HR) 1.44; 95% CI, 0.93 to 2.23) and non-overdose related mortality (HR 1.74; 95% CI 1.00 to 3.01) with MAT and benzodiazepine treatment; however, these data were not deemed statistically significant. Although the results indicated an increased risk of fatal overdose, non-overdose mortality, and all-cause mortality during periods of coadministration of MAT and non-benzodiazepines, only the data for fatal overdose and all-cause mortality reached statistical significance; HR 2.34 (95% CI, 1.37 to 3.99) and HR 1.33 (95% CI, 1.12 to 2.45), respectively. A comparison between the benzodiazepine cohort and the non-benzodiazepine cohort was not performed because the authors did not adjust for the indication of use for the drugs 3.
b) According to a study of aggregate nationwide death certificate data from 2010 to 2014, 3495 drug overdose deaths were reported in 2014. Methadone and other CNS depressants were frequently identified as culprits in those deaths. Concurrent alprazolam use was reported in 18.1% of cases, followed by oxycodone (10.1%), cocaine (9.6%), heroin (9%), and diazepam (6.6%). The FDA reported 322 drug overdose deaths in 2014 involving buprenorphine. Of these 322 deaths, 32.9% involved alprazolam, 17.4% involved clonazepam, 11.2% involved diazepam, 11.2% involved heroin, and 9.9% involved fentanyl. The absolute number of methadone-involved deaths was 10 times the number of buprenorphine-involved deaths, although confounding factors and differences in drug utilization were not accounted for. It is unknown whether the risk of overdose death with concomitant CNS depressant drugs differed between buprenorphine and methadone 3.
Common questions
Can I take Halazepam and Buprenorphine together?
Combining buprenorphine and halazepam adds up their sedative effects and can dangerously slow breathing, so use the lowest effective doses under close medical supervision and never stop either drug on your own. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Halazepam and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Halazepam and Buprenorphine interaction managed?
What your care team may do: Prefer avoiding the combination, often by tapering the benzodiazepine or reducing to the lowest effective dose. Consider non-benzodiazepine alternatives for anxiety or insomnia. If both are truly needed, monitor you more closely for sedation and breathing changes, sometimes in a higher level of care. What you should do: Keep taking both exactly as prescribed unless told… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Halazepam or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: SUBUTEX(R) sublingual tablets, buprenorphine sublingual tablets. Indivior Inc (per FDA), North Chesterfield, VA, 2021. DailyMed
- US Food and Drug Administration (FDA): Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. US Food and Drug Administration (FDA). Silver Spring, MD. 2017.
Keep reading about Buprenorphine
Keep reading about Halazepam
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist